SCHEMBL5281604

SCHEMBL5281604

CCCN(C(=O)C1CCCN(S(=O)(=O)c2ccccc2C(=O)OC)C1)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.52
CYP19A1 P11511 1/20 0.51
ALDH1A1 P00352 5/20 0.49
KDM4E B2RXH2 4/20 0.49
LMNA P02545 3/20 0.49
HTT P42858 2/20 0.49
GAA P10253 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
TSHR P16473 2/20 0.47
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
GFER P55789 1/20 0.47
CYP2C19 P33261 1/20 0.46
MAPK1 P28482 1/20 0.44
ATM Q13315 1/20 0.44
TP53 P04637 1/20 0.43
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6002179 0.81 CYP19A1 (0.51) HSD17B10CYP19A1ALDH1A1KDM4ELMNA
SCHEMBL6003604 0.81 HSD17B10 (0.53) HSD17B10CYP19A1ALDH1A1KDM4ELMNA
SCHEMBL5243246 0.76 CYP19A1 (0.59) HSD17B10CYP19A1ALDH1A1KDM4ELMNA
SCHEMBL5245897 0.75 HSD17B10 (0.55) HSD17B10CYP19A1ALDH1A1KDM4ELMNA
SCHEMBL8337431 0.73 CA1 (0.58) HSD17B10CYP19A1ALDH1A1LMNASMN1; SMN2
SCHEMBL5245026 0.71 GAA (0.58) HSD17B10CYP19A1ALDH1A1KDM4ELMNA
SCHEMBL7072831 0.69 MMP2 (0.73) HSD17B10CYP19A1ALDH1A1KDM4ELMNA
SCHEMBL6541167 0.68 L3MBTL1 (0.53) ALDH1A1KDM4ELMNAGAATSHR
SCHEMBL25292551 0.67 NPC1 (0.55) ALDH1A1TSHRKMT2ACYP2C19
SCHEMBL25292552 0.67 NPC1 (0.55) ALDH1A1TSHRKMT2ACYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1866285-A1 1-SULFONYL-PIPERDINE-3-CARBOXYLIC ACID AMIDE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE FOR THE TREATMENT OF TYPE II DIABETES MELLITUS F. Hoffmann-Roche AG (CH) 2007-12-19 EP claimed
WO-2006094633-A1 1- SULFONYL-PI PERDINE- 3 -CARBOXYL I C ACID AMIDE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE FOR THE TREATMENT OF TYPE II DIABETES MELLITUS F. HOFFMAN-LA ROCHE AG (CH) 2006-09-14 WO claimed
US-20060199816-A1 Aryl sulfonyl piperidines GILLESPIE PAUL 2006-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199816-A1 Aryl sulfonyl piperidines GPR119, SLC5A2, GLS2 HSD17B10 866/4885CYP19A1 380/4885ALDH1A1 88/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.